Heron Therapeutics (HRTX) Earnings Analysis

Heron Therapeutics (HRTX) next reports earnings on 2026-08-14, consensus EPS -0.02 USD. Last quarter (2026-05-11) it missed with EPS -0.04 USD vs -0.03 USD est (-33.3%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E -2.64.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does HRTX next report earnings?

Next earnings date2026-08-14
Consensus EPS estimate-0.02 USD
Revenue estimate0.04B

HRTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11-0.04 USD-0.03 USD-33.3%Miss
2026-02-26-0.02 USD-0.03 USD+33.3%Beat
2025-08-08-0.02 USD-0.01 USD-100%Miss
2025-02-270.02 USD-0.03 USD+166.7%Beat

Beat rate: 2/4 (50%) over reported quarters with consensus data.

HRTX valuation and analyst view

Trailing P/E-2.64
Trailing EPS-0.16315 USD
Price / book9.71
Dividend yield0.00%
Market cap0.08B
Analyst consensusBuy (18 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is Heron Therapeutics (HRTX)'s next earnings date?

Heron Therapeutics is next scheduled to report on 2026-08-14, with a consensus EPS estimate of -0.02 USD and revenue estimate of 0.04B.

Did HRTX beat earnings last quarter?

In its 2026-05-11 report, HRTX posted EPS of -0.04 USD versus a -0.03 USD estimate — a miss of 33.3%.

What is HRTX's earnings track record?

Over the last 4 reported quarters with consensus data, HRTX beat estimates 2 times (50%).

What is HRTX's current P/E ratio and EPS?

HRTX trades at a trailing P/E of -2.64 on trailing EPS of -0.16315134513778304 USD.

What do analysts rate HRTX?

Analyst consensus is "Buy" across 19 ratings (0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell).